What other stocks do shareholders of Oncobiologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncobiologics investors own include CRISPR Therapeutics (CRSP) , Network-1 Technologies (NTIP) , Allena Pharmaceuticals (ALNA) , Intra-Cellular Therapies (ITCI) , Cidara Therapeutics (CDTX) , Neuralstem (CUR) , Exelixis (EXEL) , Fate Therapeutics (FATE) , Ampliphi Biosciences (APHB) and Ardelyx (ARDX) .

When did Oncobiologics IPO?

Oncobiologics (ONS) raised $35 million in an IPO on Friday, May 13th 2016. The company issued 5,800,000 shares at $6.00 per share. Jefferies and Barclays acted as the underwriters for the IPO and Cantor Fitzgerald & Co. was co-manager.

NASDAQ:ONS

Oncobiologics (ONS) Stock Price, News & Analysis

→ Now Open: Crypto emergency update (From InvestorPlace) (Ad)

Free ONS Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $8.12
▼
$8.84
50-Day Range: $0.72
▼
$7.40
52-Week Range: $0.57
▼
$1.53

Volume: 234,340 shs
Average Volume: 69,024 shs
Market Capitalization: $598.54 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Social Media

Get Oncobiologics alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Oncobiologics Stock (NASDAQ:ONS)

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification, development, manufacture, and commercialization of ONS-5010/LYTENAVA as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

ONS Stock News Headlines

August 2, 2023 | mirror.co.uk

BBC slammed for 'biased' Wimbledon coverage of Marketa Vondrousova vs Ons Jabeur final

July 30, 2023 | mirror.co.uk

Ons Jabeur ‘kicked off’ Wimbledon centre court moments before women’s final

April 19, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 27, 2023 | nytimes.com

Are Away Carry-Ons Worth the Hype?

October 5, 2022 | dailymail.co.uk

ONS - the Office of National Statistics

See More Headlines

Receive ONS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncobiologics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological Products, Except Diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:ONS
Previous Symbol: NYSE:ONS
CUSIP: N/A
CIK: 1649989
Web: www.oncobiologics.com
Phone: (609) 619-3990
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-38,840,000.00
Net Margins: -464.47%
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -93.28%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.41
Quick Ratio: 0.41

Sales & Book Value

Annual Sales: $3.81 million
Price / Sales: 157.10
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.36) per share
Price / Book: -6.10

Miscellaneous

Outstanding Shares: 72,200,000
Free Float: N/A
Market Cap: $598.54 million
Optionable: Not Optionable
Beta: -0.27

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Lawrence A. Kenyon
President, CEO, CFO, Secretary & Treasurer
Terry Dagnon
Chief Operating Officer
Jennifer M. Kissner
Senior Vice President-Clinical Development
Jeff Evanson
Chief Commercial Officer

Key Competitors

View All Competitors

ONS Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Oncobiologics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Oncobiologics investors own include CRISPR Therapeutics (CRSP), Network-1 Technologies (NTIP), Allena Pharmaceuticals (ALNA), Intra-Cellular Therapies (ITCI), Cidara Therapeutics (CDTX), Neuralstem (CUR), Exelixis (EXEL), Fate Therapeutics (FATE), Ampliphi Biosciences (APHB) and Ardelyx (ARDX).
When did Oncobiologics IPO?: Oncobiologics (ONS) raised $35 million in an IPO on Friday, May 13th 2016. The company issued 5,800,000 shares at $6.00 per share. Jefferies and Barclays acted as the underwriters for the IPO and Cantor Fitzgerald & Co. was co-manager.

This page (NASDAQ:ONS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Oncobiologics (ONS) Stock Price, News & Analysis

About Oncobiologics Stock (NASDAQ:ONS)

ONS Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ONS Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info